David G. Maloney, MD, PhD, on ALL: New Therapeutic Agents

2017 NCCN Hematologic Malignancies Congress

David G. Maloney, MD, PhD, of the Fred Hutchinson Cancer Research Center, reviews the clinical data and ongoing trials evaluating immunotherapy in the setting of relapsed or refractory acute lymphocytic leukemia and discusses major adverse events of treatment.

Related Videos

Hematologic Malignancies

Ruben A. Mesa, MD, on Myeloproliferative Neoplasms: Managing PV and ET

Ruben A. Mesa, MD, of The University of Texas Health San Antonio Cancer Center, discusses the role of JAK2 inhibitors in treating polycythemia vera and essential thrombocythemia an...

Lymphoma

Ranjana H. Advani, MD, on Hodgkin Lymphoma: New Management Options

Ranjana H. Advani, MD, of Stanford Cancer Institute, discusses the novel immunomodulatory agents used to manage patients with relapsed or refractory Hodgkin lymphoma.

Leukemia

Bruno C. Medeiros, MD, on AML: Targeted Treatment

Bruno C. Medeiros, MD, of Stanford Cancer Institute, discusses emerging novel agents and targeted molecular abnormalities in the management of acute myeloid leukemia.

Leukemia

William G. Wierda, MD, PhD, on CLL: How to Sequence Therapy

William G. Wierda, MD, PhD, of The University of Texas MD Anderson Cancer Center, discusses sequencing therapy in patients with relapsed/refractory CLL/SLL based on prior treatment...

Lymphoma

Jane N. Winter, MD, on Follicular Lymphoma: Treatment Updates

Jane N. Winter, MD, of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, discusses the use of novel targeted therapies for newly diagnosed and relapsed/re...

Advertisement

Advertisement



;
Advertisement

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.